FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.

By
Kathryn Wighton
March 13, 2026
2 min

MDSpire News

1

The FDA has approved secukinumab for adolescents aged 12 and older with moderate to severe hidradenitis suppurativa.
2

Secukinumab is the only interleukin-17A inhibitor approved for pediatric patients with hidradenitis suppurativa.
3

This approval provides a new biologic treatment option for adolescents with limited options for managing HS.
4

Hidradenitis suppurativa is a chronic inflammatory disorder that often begins during adolescence.
5

The approval was supported by adult HS studies and pediatric clinical trial data from other indications.

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

1

2

3

4

5

Original Source(s)

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Related Content

Impact of sensory training on healthcare provider care for neurodivergent children

Pediatric home-based central venous access device dressings: Medical liquid adhesive versus standard care to reduce dressing disruption: The STICKY-kids RCT protocol

The efficacy of tonsillectomy in the management of PFAPA syndrome: a systematic review and meta-analysis